Canopy Growth Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Regeneron Pharmaceuticals Inc trades at $653.1 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 172.6× Canopy Growth Corp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | REGN | |
|---|---|---|
Market Cap | $398.46M | $68.79B |
Sector | Health | Health |
52-Week High | $1.92 | $812.27 |
52-Week Low | $0.86 | $542.52 |
Enterprise Value | $337.90M | $62.74B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →